239 related articles for article (PubMed ID: 15772291)
1. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
[TBL] [Abstract][Full Text] [Related]
2. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Wadkins RM; Silman I; Sussman JL; Potter PM
Chem Biol Interact; 2005 Dec; 157-158():153-7. PubMed ID: 16289500
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
Hyatt JL; Tsurkan L; Morton CL; Yoon KJ; Harel M; Brumshtein B; Silman I; Sussman JL; Wadkins RM; Potter PM
Chem Biol Interact; 2005 Dec; 157-158():247-52. PubMed ID: 16257398
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into CPT-11 activation by mammalian carboxylesterases.
Bencharit S; Morton CL; Howard-Williams EL; Danks MK; Potter PM; Redinbo MR
Nat Struct Biol; 2002 May; 9(5):337-42. PubMed ID: 11967565
[TBL] [Abstract][Full Text] [Related]
5. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
[TBL] [Abstract][Full Text] [Related]
6. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
7. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
8. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.
Morton CL; Wadkins RM; Danks MK; Potter PM
Cancer Res; 1999 Apr; 59(7):1458-63. PubMed ID: 10197614
[TBL] [Abstract][Full Text] [Related]
9. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Danks MK; Morton CL; Pawlik CA; Potter PM
Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
12. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.
Guichard SM; Morton CL; Krull EJ; Stewart CF; Danks MK; Potter PM
Clin Cancer Res; 1998 Dec; 4(12):3089-94. PubMed ID: 9865925
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.
Dodds HM; Hanrahan J; Rivory LR
Anticancer Drug Des; 2001; 16(4-5):239-46. PubMed ID: 12049482
[TBL] [Abstract][Full Text] [Related]
14. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
15. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
Sai K; Kaniwa N; Ozawa S; Sawada JI
Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529
[TBL] [Abstract][Full Text] [Related]
16. The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design.
Greenblatt HM; Guillou C; Guénard D; Argaman A; Botti S; Badet B; Thal C; Silman I; Sussman JL
J Am Chem Soc; 2004 Dec; 126(47):15405-11. PubMed ID: 15563167
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
Bartolucci C; Siotto M; Ghidini E; Amari G; Bolzoni PT; Racchi M; Villetti G; Delcanale M; Lamba D
J Med Chem; 2006 Aug; 49(17):5051-8. PubMed ID: 16913695
[TBL] [Abstract][Full Text] [Related]
19. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Dodds HM; Rivory LP
Mol Pharmacol; 1999 Dec; 56(6):1346-53. PubMed ID: 10570064
[TBL] [Abstract][Full Text] [Related]
20. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates.
Dvir H; Wong DM; Harel M; Barril X; Orozco M; Luque FJ; Muñoz-Torrero D; Camps P; Rosenberry TL; Silman I; Sussman JL
Biochemistry; 2002 Mar; 41(9):2970-81. PubMed ID: 11863435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
